Viatris Inc.
General ticker "VTRS" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $11.9B (TTM average)
Viatris Inc. follows the US Stock Market performance with the rate: 38.1%.
Estimated limits based on current volatility of 0.7%: low 10.73$, high 10.87$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-08-22, amount 0.12$ (Y4.46%)
- Total employees count: 32000 as of 2024
- China accounted for 13.3% of revenue in the fiscal year ended 2024-12-31
- US accounted for 23.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Dependence on key products, Regulatory and compliance, Supply chain disruptions, Currency fluctuations, Strategic risks and growth management
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.40$, 15.02$]
- 2025-12-31 to 2026-12-31 estimated range: [8.94$, 14.53$]
Financial Metrics affecting the VTRS estimates:
- Positive: with PPE of 4.7 at the end of fiscal year the price was very low
- Positive: -3.60 < Operating profit margin, % of 0.07
- Positive: Operating cash flow per share per price, % of 15.55 > 13.24
- Negative: negative Industry operating cash flow (median)
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of -1.51
- Negative: 41.86 < Shareholder equity ratio, % of 44.90 <= 63.39
Short-term VTRS quotes
Long-term VTRS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $16,258.30MM | $15,315.30MM | $14,388.40MM |
| Operating Expenses | $14,643.40MM | $14,549.10MM | $14,378.30MM |
| Operating Income | $1,614.90MM | $766.20MM | $10.10MM |
| Non-Operating Income | $1,198.30MM | $-563.30MM | $-633.30MM |
| Interest Expense | $592.40MM | $573.10MM | $550.00MM |
| R&D Expense | $698.60MM | $910.70MM | $837.00MM |
| Income(Loss) | $2,813.20MM | $202.90MM | $-623.20MM |
| Taxes | $734.60MM | $148.20MM | $11.00MM |
| Profit(Loss)* | $2,078.60MM | $54.70MM | $-634.20MM |
| Stockholders Equity | $21,072.30MM | $20,467.40MM | $18,635.50MM |
| Inventory | $3,519.50MM | $3,469.70MM | $3,854.10MM |
| Assets | $50,022.20MM | $47,685.50MM | $41,500.90MM |
| Operating Cash Flow | $2,999.00MM | $2,900.00MM | $2,302.90MM |
| Capital expenditure | $489.40MM | $474.50MM | $326.00MM |
| Investing Cash Flow | $1,474.10MM | $-864.50MM | $1,800.70MM |
| Financing Cash Flow | $-3,877.90MM | $-2,301.90MM | $-4,330.40MM |
| Earnings Per Share** | $1.71 | $0.05 | $-0.53 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.